Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Investment Securities: 2012-2025

Historic Gains from Investment Securities for Agios Pharmaceuticals (AGIO) over the last 10 years, with Sep 2025 value amounting to $65,000.

  • Agios Pharmaceuticals' Gains from Investment Securities rose 291.18% to $65,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 180.84%. This contributed to the annual value of $39,000 for FY2024, which is 107.05% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Gains from Investment Securities stood at $65,000, which was down 95.06% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Gains from Investment Securities ranged from a high of $6.1 million in Q2 2021 and a low of -$8.3 million during Q4 2021.
  • Its 3-year average for Gains from Investment Securities is $95,818, with a median of $150,000 in 2023.
  • The largest annual percentage gain for Agios Pharmaceuticals' Gains from Investment Securities in the last 5 years was 7,009.30% (2021), contrasted with its biggest fall of 9,795.35% (2021).
  • Over the past 5 years, Agios Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at -$8.3 million in 2021, then skyrocketed by 101.00% to $83,000 in 2022, then plummeted by 2,677.11% to -$2.1 million in 2023, then spiked by 131.60% to $676,000 in 2024, then spiked by 291.18% to $65,000 in 2025.
  • Its Gains from Investment Securities stands at $65,000 for Q3 2025, versus $1.3 million for Q2 2025 and $188,000 for Q1 2025.